Background: Growth hormone has been used as an adjunct in ovarian stimulation of IVF cycles for the past three decades. However, the exact mechanism of its role in improving oocyte quality has not been thoroughly investigated. Although a clear indication for GH co-treatment is in infertile women with GH deficiency, GH has been given mostly to poor ovarian responders. Method: This paper is a review of the most recent published data on the role of GH supplementation in improving oocyte quality in younger women who are suboptimal or unexpected poor responders to standard ovarian stimulation. Results: Retrospective cohort and randomized trials demonstrated an improvement in oocyte quality through morphological parameters, mitochondrial function, biomarkers, GH receptors, insulin growth factor, markers of oxidative stress, mature oocytes, good quality embryos, implantation rate, clinical pregnancy and live birth. Conclusion Current data suggest GH supplementation may improve oocyte and embryo qualities, endometrial receptivity, clinical pregnancy and live birth. However, better quality evidence is needed before a recommendation can be made for GH supplementation to be given to infertile women who are suboptimal or poor ovarian responders.
growth hormone ; hormone receptor ; IGF-1 ; IVF

The need for simplified in-vitro fertilization (IVF) treatment approaches with the aim of reducing treatment burden and to prevent drop-outs after a failed IVF cycle can be met by the use of corifollitropin alfa for COS in association with a GnRH antagonist protocol. This is a report of the first local case of a successful pregnancy using corifollitropin alfa in IVF. This is a case of a 33-year-old G3 P0 (0030) whose partner has teratozoospermia, COS using corifollitripin alfa yielded eight mature oocytes with no occurrence of OHSS. Six oocytes were fertilized using ICSI with six good quality embryos reaching cleavage stage. Two grade 1 embryo sat day 3 cleavage stage were transferred. A clinical pregnancy was documented at 7 weeks age of gestation. Congenital anomaly scanning at 24 weeks age of gestation revealed a grossly normal fetus. Patient delivered a healthy, live, term baby boy. Review of literature suggests that corrifollitropin alfa is as effective as rFSH in delivering live birth rate, ongoing pregnancy rate and clinical pregnancy rate. The sustained and higher FSH immunoreactivity concentrations and the inability for dose adjustment after treatment with a single dose of corifollitropin compared with the daily rFSH regimen underscored the need for careful patient selection in the use of corifollitropin alfa.

Human ; Female ; Adult ; Corifollitropin Alfa (elonva) ; Recombinant Follicle Stimulating Hormone (rfsh) ; Controlled Ovarian Stimulation (cos) ; In Vitro Fertilization (ivf) ; Intracytoplasmic Sperm Injection (icsi)

Background: Fecondation invitro is an outstanding scientific progression in the 20th century. Beside the technical factor and choosing a schedule to reach the fertility rate of high pregnancy, the thickness of uterine endothelium can\u2019t be let pass unnoticed because it is a favorable factor for the embryons which can made easily the foyer in the uterine. Objective: To define the relation between the thickness of uterine endothelium with a concentration of estradiol plasma in the day when injecting hCG with the result of pregnancy. Subject and Method: A retrospective study with research in to 294 cases of IVF. Result: 58.9% is secondary infertile with the average age between 32.6 +/-5.4 who have been infertile in the timescale of 6.4+/-5.0 years. Injecting hCG to take ovocyte when the average estradiol concentradiol is 2378 +/- 1335.9 pg/ml and the estradiol concentration of ovule is 251.4pg/ml. Conclusion: The higher the estradiol concentration is, the thicker the uterine endothelium is. 7.3% cases had uterine endothelium thicker than 10mm if the estradiol concentration is higher than 3000pg/ml. The rate of people who are clinically pregnant with the uterine endothelium > 10mm is 2.24 times higher than the rate of people who are clinically pregnant with the uterine endothelium < 10mm.
Infertile ; Fecondation invitro (IVF) ; Uterine endothelium ; Clinically pregnant.

Background: Ovarian stimulation is an important process in IVF. Objectives:To assess the efficacy of low dose GnRH agonist depot in combination with recombinant FSH for ovarian stimulation in IVF and evaluate the clinical pregnancy rate of this protocol. Subject and method: A prospective study recruited 60 patients undergoing IVF. The patients was injected intramuscularly with a single dose of diphereline of 1.25 mg on cycle day 21-23. Then recombinant FSH was given subcutaneously on day 3. hCG was injected intramuscularly when at least one follicle reached 18 mm in diameter. Oocytes retrieval in 36 hours and embryo 2 transfer on day after oocytes retrieval. Results: Duration of stimulation was 10.8 \xb1 0.9, average number of oocytes was 3.3 \xb1 4.7, average number of embryos was 6.5 \xb1 4.1, clinical pregnancy rate was 41.7%. Ovarian hyperstimulation rate was 5%, frozen embryo rate was 40 %. Conclusions: The use of low dose GnRH agonist depot in combination with recombinant ISH is effective for ovarian stimulation in IVF.
In vitro Fertilization (IVF) ; Ovarian stimulation ; Oocytes retrieval ; Embryo transfer ; GnRH agonist